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Available online xxxxIntroduction: Research into the optimal management of frail patients with cancer is limited and treatment
decision-making in this cohort can be difficult. A number of measures have been developed to assess frailty,
but few studies explore the correlation between frailty measures and cancer treatment outcomes.
Methods: This retrospective cohort study is an exploratory analysis of the GO2 randomised controlled trial. GO2
recruited both older and frail younger patients commencing first-line palliative chemotherapy for advanced
gastro-oesophageal (aGO) cancer. This analysis aims to explore the correlation between baseline frailty and
treatment outcome. Baseline frailty measures were derived from clinical data and included ECOG Performance
Status (PS), the GO2 Frailty Score (GO2FS), Geriatric-8 (G8), Cancer and Aging Research Group (CARG) toxicity
score and a ‘modified’ Rockwood Clinical Frailty Scale (mCFS). Novel patient-centred composite measure Overall
TreatmentUtility (OTU)was the primary endpoint. Ordinal logistic regressionwas undertaken to give odds ratios
for poor vs good/intermediate OTU. Secondary endpoints were progression-free and overall survival. Models
were adjusted for age, sex, histology, metastases, Trastuzumab and renal/hepatic function.
Results: In GO2, 514 patients were randomised between three chemotherapy dose-levels; all of these patients
were assessed for OTU and are included in this analysis. Worse GO2FS, mCFS and G8 scores all had a statistically
significant association with poor (vs good/intermediate) OTU, progression and death, which persisted after ad-
justment. Adjusted odds ratios for poor OTU amongst those with the worst GO2FS and mCFS and best G8 scores
were as follows: 1.85 (95% confidence interval [CI] 1.20–2.88) for GO2FS ≥3 (‘severely frail’), 1.72 (1.19–2.50) for
mCFS 5+ (‘frail’) and 0.57 (0.32–1.00) for G8 > 14 (‘normal’). Worse ECOG PS and CARG scores did not have a
statistically significant association with poor OTU/progression/death.
Conclusion: In this study, frailty identified via GO2FS, mCFS and G8 conveyed a statistically significant increased
risk ofworse treatment outcome in older and frail younger patientswith aGO cancer. Frailty assessment provides
information over and above PS and should be integrated alongside routine assessments in research and clinical
practice. In the absence of prospective data, frailty measures can be derived retrospectively to build the evidence
base around optimal care of frailer patients.








Frailty due to older age or co-morbidities is common in patients with
cancer and is associatedwith an increased risk of treatment complicationsl Research at St James, Beckett
. This is an open access article under
son, D. Cairns, et al., Frailty a
, https://doi.org/10.1016/j.jgo[1]. Despite this, many clinical trials exclude older and frail younger pa-
tients, so evidence to guide optimalmanagement is lacking. EasternCoop-
erative Oncology Group (ECOG) Performance Status (PS) is the most
widely used tool for assessing fitness for systemic anticancer therapy
(SACT), but lacks granularity [2] and a number of criticisms have been
highlighted [3]. TheRockwoodClinical Frailty Scale [4] (CFS) is a global as-
sessment of fitness which has extensive evidence of correlationwith out-
come in a range of acute andoutpatient settings, andhas been adopted for
use by the NHS Specialised Clinical Frailty Network (SCFN) in the Unitedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
nd treatment outcome in advanced gastro-oesophageal cancer: An
.2021.12.009
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[6,7] but remains largely untested in the oncology setting.
Frailty screening tools to guide intervention and management of
older cancer patients recommended by ASCO guidelines [8] include
the Geriatric-8 (G8) [9] and Vulnerable Elders Survey (VES)-13 [10],
whichhave both been independently associatedwith adverse outcomes
in older patientswith cancer receiving chemotherapy. Additionally, two
toxicity prediction tools are recommended which have been demon-
strated to provide estimates of risk of significant (grade ≥ 3) chemother-
apy toxicity in older patients with cancer; Cancer and Aging Research
Group (CARG) [11] and Chemotherapy Risk Assessment Scale for
High-Age Patients (CRASH) [12].
The aim of this study is to explore the correlation between baseline
frailtymeasures and global treatment outcomes in older and frail younger
patientswith advanced gastro-oesophageal (aGO) cancer in the GO2 trial.
The GO2 trial is a phase III randomised-controlled trial which sought to
optimise chemotherapy dosing for older and frail younger patients with
aGO cancer, and established 60% duplet chemotherapy as a new standard
of care for these patients [13]. It also incorporated the novel patient-
centred composite end-point Overall Treatment Utility (OTU) as a global
measure of treatment outcome. OTU is categorised as Good, Intermediate
or Poor by combining a range of factors particularly relevant to frail and
older patients with advanced cancer, including clinical efficacy, toxicity,
tolerability, and the patient's own assessment of treatment value (see
Fig. 1). GO2 is one of the largest studies prospectively exploring the treat-
ment of older and frail younger patients, and extensive baseline data col-
lected through geriatric assessment (GA) provides a unique opportunity
to explore the correlation between frailty and treatment outcomes.
2. Methods
A retrospective cohort studywas undertaken as an exploratory anal-
ysis of the GO2 randomised controlled trial database.
2.1. Participants
The GO2 study recruited patients from 52 sites across the UK with
aGO cancer (carcinoma of the oesophagus, gastroesophageal junction
or stomach) who were deemed unsuitable for full-dose combination
chemotherapy due to advanced age and/or frailty. Further details
about eligibility and recruitment can be found in the publication of the
primary analysis and trial protocol [13]. All patients in the CHEMO-Fig. 1. Overall treatment utility (O
For colour reproduction on the w
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INTENSITY pathway (i.e. those being randomised between different
dose levels of chemotherapy, rather than 60% chemotherapy vs best
supportive care) were included in this analysis (514 patients).
2.2. Frailty measures
A list of potential frailty measures was obtained through literature
review and expert opinion of elderly medicine colleagues. The GO2
database was then interrogated to ascertain which measures were de-
rivable from the baseline data. Baseline data included routine demo-
graphic data and GA, including the following questionnaires: G8
and Instrumental Activities of Daily Living (IADL) (both completed
by nurse alongside patient) and two self-completed quality of life
questionnaires (European Organisation for Research and Treatment
of Cancer (EORTC) QLQ-C30 and EQ-5D-3L) as well as assessment of
impairments in 9 frailty domains which informed the pre-determined
GO2 frailty score (GO2FS, further described in Table 1).
The derivable frailtymeasures selected for evaluation in this analysis
are shown in Table 1.
[Insert Table 1] Derivable frailty measures selected for evaluation:
rationale, source and categorisation.
2.3. ‘Modified’ clinical frailty scale (mCFS)
Rockwood CFS is a simple global assessment of fitness designed to be
undertaken by a clinician. Patients are scored 1–9 based on descriptors
outlining functional capabilities, fatigue and impact of symptoms [4].
RockwoodCFSwasnot collected prospectively inGO2, but given its excep-
tional simplicity and growing use in the UK [5], we were keen to derive a
proxy measure for this study from the baseline questionnaire data. As a
piece of exploratory work, authors JP (oncology trainee), DS (oncology
consultant) and SN (elderly medicine consultant) drafted an algorithm
to derive a ‘modified’ CFS based on selected questions and responses in
the baseline assessments/questionnaires which aligned closest with the
Rockwood CFS scores and descriptors. The algorithm was independently
reviewed by two elderly medicine consultants for face validity and
amended in line with feedback until a ‘best fit’ for deriving CFS from the
available data was agreed (supplementary appendix 1). Rockwood CFS is
a 9-point scale (1 ‘Very Fit’ – 9 ‘Terminally Ill’); the modified CFS (mCFS)
was abbreviated to a 7-point scale (1 ‘Very Fit’ - 7 ‘Living with Severe
Frailty’), as patients with the extreme degree of frailty reflected by a
Rockwood CFS >7 would not have been considered eligible for GO2 onTU) scoring in the GO2 trial.
eb and in print.
Table 1
Derivable frailty measures selected for evaluation: rationale, source and categorisation.
Frailty measure Rationale for selection Source of data Type of data and categorisation
ECOG Performance
Status
Used routinely in the assessment of
fitness for SACT





assessment-based frailty measure for
the GO2 study based on published
literature [1]
Measured prospectively by assessing impairment (yes/no)
in 9 frailty domains: weight loss, mobility, falls,
neuropsychiatric, physical functioning, social functioning,
mood, fatigue, and polypharmacy
Numeric: Number of domains with impairments,
out of 9
Categorical: Not frail (0–1/9 domain impaired),
Mildly frail (2/9 domains impaired), Severely frail




Global assessment of frailty,
potentially easy to undertake but not
yet tested in this setting
7-point scale based on the Rockwood Clinical Frailty Scale
[4]. Derived retrospectively via an algorithm from
questionnaire data regarding patients' function, fatigue and
impact of symptoms/disease (supplement 1).
Numeric: Score 1–7
Categorical: Fit (1–2), Pre-frail (3–4), Frail
(5+) – guided by feedback expert review and
findings of statistical analysis
Geriatric-8[9] Frailty screening tool recommended
by ASCO consensus guidelines [8]
8-item questionnaire collected prospectively encompassing
food intake, weight loss, mobility, neuropsychological
problems, BMI, polypharmacy, self-rated health and age.
Numeric: Total score of 0–17 (lower scores align
with adverse features)
Categorical: >14 (‘normal’), ≤14 (‘abnormal’) –





recommended by ASCO consensus
guidelines [8]
11 items encompassing age, cancer type, chemotherapy
schedule, functioning, anaemia and kidney function. Derived
retrospectively.
Numeric: Total score of 0–19 (higher scores
reflecting adverse features).
Categorical: Low risk (0–5), Medium risk (6–9),

















Planned use of Trastuzumab
Yes 28 (5.4%)
No 486 (94.6%)
Dose reduction due to renal/hepatic function
Yes 45 (8.8%)
No 469 (91.2%)
J. Pearce, D. Swinson, D. Cairns et al. Journal of Geriatric Oncology xxx (xxxx) xxxfitness grounds, and additionally because the baseline questionnaire data
was unable to reliably identify patients whom fulfilled the descriptors for
Rockwood CFS scores of 8 (‘Living with very severe frailty’) or 9 (‘Termi-
nally ill’).
2.4. Outcomes
Overall Treatment Utility (OTU), measured at 9 weeks, was selected
as the primary outcome for this analysis due to its ability to provide a
global, holistic measure of treatment outcome [14] (see Fig. 1). Second-
ary outcomes are progression-free and overall survival. Study endpoints
are fully defined in the trial protocol and statistical analysis plan [13]
and conform to the joint EORTC/International Society of Geriatric Oncol-
ogy (SIOG) Statement [15].
2.5. Statistical analyses
The coding platform Rstudio was used to calculate frailty scores and
undertake statistical analyses. OTU comparisons used ordinal logistic re-
gression to estimate odds ratios (ORs) for a poor vs good or intermediate
OTU with 95% confidence intervals (CIs). Cox proportional hazards (CPH)
regression [16] were used to estimate hazards ratios (HRs) and 95% CIs
and Kaplan-Meier methods [17] were used to estimate survivor functions
for time-to-event endpoints. Numeric and grouped data was used for the
ordinal logistic regression, and grouped data for CPH regression. Analyses
for all frailtymeasureswere treated and reported in the sameway, for con-
sistency and to allow comparison between ORs and HRs for each frailty
measure. Groupings and rationale for GO2FS, CARG and G8 are outlined
in Table 1. Models were adjusted for potential confounders: age group,
sex, histology, distant metastases, planned use of Trastuzumab and dose
reduction due to renal or hepatic function. Performance statuswas also ad-
justed for in additional analyses of GO2FS, mCFS, G8 and CARG, to provide
an indication as towhether these scores add information on top of the cur-
rent standard of care in fitness assessment (PS), but was not included in
the final adjustment for consistency and due to concerns regarding co-
linearity between frailty measures and PS. Variable Inflation Factors (VIF)
testing was undertaken on each model to look for multi-collinearity.
2.6. Ethics
Ethical approval for the GO2 trial was provided by the UK National




In GO2, 514 patients were randomised between three chemotherapy
dose-levels; all of them underwent baseline GA, were assessed for OTU,
and are included in this analysis. No patients were lost to follow-up and
the median follow-up time was 12.6 months [IQR 11.9, 12.9]. Baseline pa-
tient characteristics are shown in Table 2. Frailty measures, stratified by
treatment outcomes across all treatment allocations are summarised in
Table 3.
3.2. Odds ratios for poor OTU
Odds ratios for numeric and categorical frailty measure scores, be-
fore and after adjustment, are displayed in Table 4.
Performance status was not associated with a statistically significant
increased risk of poorOTU,with an adjusted odds ratio of 1.25 (0.99–1.58)
in the numeric analyses.
Table 3
Percentage of all patients within each frailty score category, whole cohort and stratified by treatment outcome.
OTU @ 9 weeks Progressed Died
X. Total Good Int. Poor No Yes No Yes








































































































































































































































































































































Abbreviations: OTU=overall treatment utility, ECOG=Eastern Cooperative OncologyGroup, PS Performance Status, GO2FS=GO2 Frailty Score, mCFS= ‘modified’ Clinical Frailty Scale,
G8 = Geriatric-8, CARG= Cancer and Aging Research Group.
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ated with poor OTU, with adjusted odds ratios of 1.19 (1.06–1.33),
1.14 (1.02–1.27) and 0.91 (0.85–0.97) respectively in the numeric anal-
yses. This suggests thatwith each point increase inGO2FS andmCFS, the
risk of a poorOTU increases by 18% and 14% respectively on the log odds
scale. In categorical analyses, the highest GO2FS andmCFS scores are as-
sociatedwith a risk of poor OTUwhich increased by 85% (for GO2FS ≥3)
and 72% (for mCFS 5+), respectively, though intermediate scores did
not demonstrate a significant association. Conversely, with each point
increase in G8, the risk of a poor OTU falls by 9%. However, the highest
G8 scores were not significantly associated with a risk of a poor OTU
in this analysis, with an adjusted odds ratio of 0.57 (0.32–1.00 [rounded
down]) for G8 > 14.
CARG score was not significantly associated with risk of poor OTU
pre-adjustment, but was after adjustment with an odds ratio of 1.07
(1.00 [rounded down] -1.13) in the numeric analyses and 2.10
(1.07–4.17) for the high-risk category (CARG score 10–19).4
3.3. Hazard ratios for progression and death
Cox proportional hazards regression estimated HRs for progression
and death respectively, adjusted and unadjusted HRs are displayed in
Table 5. Overall survival curves stratified by each frailty measure are
available in Supplementary Appendix 2.
A performance status of 2 was associatedwith an unadjusted hazard
ratio of 1.44 (1.06–1.95) for progression and 1.46 (1.06–2.01) for death,
but the statistical significance did not remain after adjustment for co-
variates. Other PS scores did not have a statistically significant correla-
tion with survival outcomes before or after adjustment.
High GO2FS and mCFS scores and low G8 scores were associated
with a statistically significant increased risk of both progression and
death. Adjusted hazard ratios for death were as follows: 1.66
(1.25–2.20) for GO2FS ≥3 (severely frail), 1.71 (1.29–2.28) for mCFS
3–4 (pre-frail), 1.75 (1.37–2.22) for mCFS 5+ (frail) and 0.54
(0.36–0.82) for G8 > 14 (‘normal’). All of these associations remained
Table 4
Odds ratios poor vs good/intermediate Overall Treatment Utility (measured at 9 weeks)
by frailty score (numeric) and category (for each frailty measure).
Overall treatment utility
Odds ratio (OR) for poor vs
good/intermediate OTU, calculated





PS score numericb 1.25 (0.99, 1.56) 1.25 (0.99, 1.58)
PS category 0 1 1
1 1.38 (0.86, 2.25) 1.40 (0.86, 2.28)
2 1.65 (0.98, 2.81) 1.65 (0.97, 2.84)
>2 1.83 (0.65, 5.25) 1.88 (0.64, 5.52)
GO2FS score numeric 1.18 (1.06, 1.33) 1.19 (1.06, 1.33)c
GO2FS category Not frail (0–1) 1 1
Frail (2) 1.23 (0.74, 2.04) 1.23 (0.74, 2.06)
Sev frail (≥3) 1.84 (1.19, 2.85) 1.85 (1.20, 2.88)c
mCFS score numeric 1.14 (1.02, 1.26) 1.14 (1.02, 1.27)
mCFS category Fit (1–2) 1 1
Pre-frail (3–4) 1.43 (0.92, 2.22) 1.45 (0.94, 2.26)
Frail (5+) 1.72 (1.19, 2.49) 1.72 (1.19,2.50)c




>14 (‘normal’) 0.58 (0.32, 1.00) 0.57 (0.32, 1.00)
CARG score numeric 1.05 (0.99, 1.11) 1.07 (1.00, 1.13)
CARG toxicity risk
category
Low (0–5) 1 1
Med (6–9) 1.43 (0.78, 2.67) 1.63 (0.84, 3.20)
High (10–19) 1.75 (0.95, 3.27) 2.10 (1.07, 4.17)b
Statistically significant results inbold. a= adjusted for: age group, sex, histology, presence
ofmetastases, planned use of trastuzumab, dose reduction due to renal or hepatic dysfunc-
tion. b = PS >2was treated as 3 for the purpose of numeric analysis. c = significant after
also adjusting for PS.
Abbreviations: OTU = overall treatment utility, PS = Performance Status, GO2FS = GO2
Frailty Score, mCFS = ‘modified’ Clinical Frailty Scale, G8 = Geriatric-8, CARG = Cancer
and Aging Research Group.
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tically significant association between CARG score and survival out-
comes, with adjusted HRs for progression of 1.13 (0.77–1.66) for
medium risk (score 6–9) and 1.25 (0.64–1.86) for high risk (score
10–19) and similar HRs for the risk of death.Table 5
Hazard ratios for progression and death (respectively) within the trial period, by frailty catego
Survival outcomes Ha
proportional hazards r
Score Unadjusted HR for
progression (CI)
PS category 0 1
1 1.01 (0.76, 1.33)
2 1.44 (1.06, 1.95)
>2 1.36 (0.74, 2.53)
GO2FS category Not frail (0–1) 1
Frail (2) 1.11 (0.83, 1.50)
Sev frail (≥3) 1.47 (1.14, 1.90)
mCFS category Fit (1–2) 1
Pre-frail (3–4) 1.54 (1.19, 2.00)
Frail (5+) 1.66 (1.34, 2.06)
G8 category ≤14 (‘abnormal’) 1
>14 (‘normal’) 0.63 (0.44, 0.90)
CARG toxicity risk category Low (0–5) 1
Med (6–9) 0.88 (0.61, 1.25)
High (10–19) 0.92 (0.64, 1.32)
Statistically significant results in bold. a = adjusted for: age group, sex, histology, presence of
b = significant after adding in PS to adjustment factors.
Abbreviations: OTU=overall treatment utility, PS=Performance Status, GO2FS=GO2 Frailty
Research Group.
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3.4. Adjustment for PS and test for co-linearity
Tables 4 and 5 give unadjusted and adjusted data. The presented ad-
justed ORs and HRs do not include adjustment for PS due to concerns
about co-linearity. PS was included in the multivariable models for
GO2FS/mCFS/G8/CARG alongside the other adjustment factors as an ad-
ditional analysis, and if significance remained, as it did in most cases,
this is indicated in the tables. Whilst PS adjustment was not included
in the presented adjusted estimates due to concerns about co-
linearity, VIF tests were undertaken on each model with the inclusion
of PS and these scores were low (<1.3) in all cases (where 1 = no cor-
relation and > 5–10 = high correlation) suggesting that even with the
inclusion of PS, multicollinearity was not present in the models.
4. Discussion
4.1. Key Findings
This retrospective cohort study explored the correlation between
frailty measures and treatment outcomes in the GO2 randomised con-
trolled trial database. Higher GO2FS and mCFS scores and lower G8
scores were associated with a statistically significant increased risk of
poor Overall Treatment Utility, progression and death. This persisted
after adjustment for confounding factors, including PS, demonstrating
that assessment of frailty adds value on top of PS. Higher PS and CARG
scores were also associated with a higher risk of poor outcome, but
this was not statistically significant (except pre-adjustment HRs for
death and progression in PS2 patients, and post-adjustment ORs for
poor OTU in the numeric CARG analysis and categorical CARG ‘high
risk’ sub-group). It may be that this study was underpowered to detect
a statistically significant difference in outcome for these measures. Haz-
ard ratios for mortality for frail patients were comparable to those re-
ported elsewhere in the literature [1].
4.2. Selection of Frailty Measures
The derivable measures selected for evaluation included a range of
measures with a potential role in assessing older and frail younger pa-
tients prior to SACT. It is important to note that whilst the CARG score
does assess some frailty domains (e.g. mobility/falls and IADLs), it isry (for each frailty measure).









0.99 (0.75, 1.31) 0.92 (0.68, 1.25) 0.93 (0.68, 1.25)
1.31 (0.96, 1.78) 1.46 (1.06, 2.01) 1.33 (0.96, 1.85)
1.27 (0.68, 2.40) 1.03 (0.51, 2.08) 0.96 (0.47, 2.00)
1 1 1
1.07 (0.79, 1.44) 1.09 (0.78, 1.51 1.09 (0.78, 1.52)
1.44 (1.11, 1.85)b 1.62 (1.23, 2.14) 1.66 (1.25, 2.20)b
1 1 1
1.57 (1.21, 2.05)b 1.65 (1.25, 2.19) 1.71 (1.29, 2.28)b
1.63 (1.30, 2.03)b 1.72 (1.35, 2.18) 1.75 (1.37, 2.22)b
1 1 1
0.63 (0.44, 0.90)b 0.54 (0.35, 0.81) 0.54 (0.36, 0.82)b
1 1 1
1.13 (0.77, 1.66) 0.88 (0.60, 1.28) 1.17 (0.78, 1.77)
1.25 (0.83, 1.86) 0.90 (0.62, 1.33) 1.26 (0.83, 1.92)
metastases, planned use of trastuzumab, dose reduction due to renal/hepatic impairment.
Score,mCFS= ‘modified’ Clinical Frailty Scale, G8=Geriatric-8, CARG=Cancer and Aging
J. Pearce, D. Swinson, D. Cairns et al. Journal of Geriatric Oncology xxx (xxxx) xxxnot a frailty assessment per-se and is designed to predict short-term
toxicity rather than longer-term outcomes. Regardless, we felt it
would be interesting and valuable to see whether this translated to
predicting global outcomes. Unfortunately, there were a number of no-
table measures, including VES-13, the Edmonton frailty score and
CRASH toxicity score, which we were unable to derive. It is also impor-
tant to note thatmany of themeasures analysed here are only validated
in specific age groups e.g. >70 for G8 [9] and > 65 for CFS [4]. We opted
to undertake all analyses on the whole cohort (including frail younger
patients), treating all frailty measures the same as far as possible. This
likely improved the power of the study to detect a statistically signifi-
cant association between frailty and outcome, but could have caused
under-estimation of the association between frailty and outcome in
older patients. Significant associations were detected despite inclusion
of all ages. Further study to validate frailty measures in younger cohorts
is warranted.
4.3. Implications of the Prognostic Capacity of Frailty Measures
Performance statuswasnot associatedwith outcome in this analysis,
further highlighting its shortcomings as a measure of fitness to guide
treatment decision-making in oncological practice. However, frailty
(identified via a range of measures) is associated with poor treatment
outcome, and that association persisted after adjusting for PS in most
cases, supporting the notion that frailty measures offer additional
value to PS in assessing fitness for and weighing risks and benefits of
SACT [2,3,6,7,11]. The correlation of frailty measures with OTU, a global
patient-centred measure of treatment outcome, highlights that of as-
sessment of frailty has prognostic value beyond traditional survival out-
comes, further emphasising their potential role of frailty assessment in
holistic decision-making. The question also remains as to whether the
assessment of frailty and understanding of the association between
frailty and outcome can be used to inform discussions and shared
decision-making alongside patients. In the initial GO2 study analysis
[13], a univariate analysis was undertaken to identify variables which
predicted OTU; frailty (via GO2FS) was one of three variables that
were independently predictive of OTU (alongside neutrophil: lympho-
cyte ratio and baseline global self-rated health via ED-5D). A multivari-
able model was created whereby each of these three variables can be
fed in to provide estimates for the probability of a good, intermediate
and poor OTU. Further study could look to further validate this model
and explore whether GO2FS could be replaced with a simpler measure
of frailty (e.g. CFS or G8) to improve the acceptability and feasibility of
applying the model in clinical practice, as a clinical and/or patient
decision-aid.
Frailty assessments are not widely undertaken in clinical trials or
clinical practice, but these findings add weight to the argument that
they should be integrated into routine practice [8,15]. The fact that the
findings are relatively consistent across a range of frailtymeasures dem-
onstrates that any measure of frailty likely has some value in decision-
making, but for widespread use a measure would need to be both vali-
dated in this setting and feasible to undertake in day-to-day practice. A
key strength of G8 is that it has been specifically developed and val-
idated in the cancer setting and is recommended in international
guidelines [8]. It can be undertaken with relative ease, but does
still require the completion of a questionnaire which can be a barrier
to use in a busy clinical environment. In contrast, CFS has been devel-
oped and widely tested in other settings [5–7], but despite its in-
creasing interest in cancer care, it is not yet validated in cancer
settings. However, it can be undertaken as part of the routine assess-
ment of a patients' symptoms, functioning and social circumstances
with no additional paperwork or assessments required, which gives
it great potential for implementation within the busy clinic setting.
We feel its simplicity and cross-speciality use make it a potentially
fantastic tool for providing a common language for assessment and
communication of frailty, spanning all specialities and professionals6
involved in cancer care, but further validation in the cancer setting is
required to support its use.
4.4. Assessment and Retrospective Derivation of Frailty in Cancer Research
This study provides proof of concept for the ability to derive a global
measure of frailty such as mCFS retrospectively from questionnaire re-
sponses in existing datasets such as clinical trials, which and could
prove valuable for studying frailty. Given that frailty is clearly a con-
founder to cancer treatment outcome, we propose that frailty should
be assessed at baseline and reported alongside demographic data in
cancer research (including observational studies and clinical trials), to
provide an understanding of the extent and outcomes of frailty within
cancer cohorts. However, in the absence of prospective frailty assess-
ment, retrospectively derived measures could have a role and where
the required data exists, the R code created for this analysis could be ap-
plied to other datasets with relative ease. For example, mCFS could be
derived from other datasets that have collected EORTC QLQ-C30 (for
mCFS 1–4), IADL (for CFS 5–6) and EQ-5D (for mCFS 7) and work is
going to identify potential datasets in which to test the algorithm. Mov-
ing forward, international consensus for the measurement and
reporting of frailty in clinical trials would be valuable.
4.5. The mCFS Algorithm and CFS
The retrospective derivation of mCFS in this analysis is a key limita-
tion of this study. In developing the algorithm to derivemCFS, it was no-
table that the baseline questionnaires did not perfectly align with the
Rockwood CFS score descriptors and there was some subjectivity
when selecting questions and responses to discriminate between CFS
scores, which highlights limitations of retrospective derivation. How-
ever, we aimed to overcome this by developing a ‘best fit’ algorithm,
recognising that mCFS is a proxy rather than a perfect measure of CFS,
and used external review to help overcome individual bias. Further de-
velopment of themCFS algorithm throughmore rigorousmethodology,
such as a formal Delphi consensus study,may help to improve the valid-
ity of themeasure.Whilst we do not knowhowwellmCFS derived from
the baseline questionnaires in this study correlates with clinician-
assessed CFS in the clinic, there is some evidence demonstrating good
inter-rater reliability between prospective and retrospective CFS assess-
ment [18], which supports the validity of the findings of this study.
Whilst this study demonstrates the potential prognostic value of the
simple CFS assessment, further study looking at the association between
prospectively-assessed CFS and treatment outcome is required before
CFS scores can be used to guide decision-making in the clinic, and pub-
lication of existing data from the SCFN pilot sites [5] that have been col-
lecting CFS in cancer settings could be valuable in this regard. A small
prospective study looking at the agreement between mCFS and CFS
could also be valuable.
5. Conclusion
Frailty, identified by three derivable measures (G8, GO2FS and
mCFS), correlates with poor Overall Treatment Utility, progression,
and death in this cohort of older and frail younger patients with aGO
cancer. Frailty measures add information over and above PS, adding
weight to the argument that assessment of frailty should be integrated
into routine clinical and research practice in oncology. The simple mea-
sure of CFS has predictive potential in this setting that is similar to other
more complex tools, though prospective study is required to corrobo-
rate the findings of this study. We have demonstrated that frailty mea-
sures can be derived retrospectively from existing data, with the
potential to help to build the evidence base around the optimal care of
frailer patients in the absence of prospectively collected frailty
measures.
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